Suche

New hope of a treatment for aggressive T-PLL leukaemia ... Hilgarth, Wolfgang R. Sperr, Peter Valent, Ingrid Simonitsch-Klupp, Richard Moriggl, Olaf Merkel, Lukas Kenner, Ulrich Jäger, Stefan Kubicek, Philipp B. Staber. Online: https://www.ncbi.nlm.nih.gov/pubmed/28972014. Blood (IF: 13.2). DOI: 10.1182/blood-2017-05-785683 Share Whatsapp Facebook Twitter... https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/2017/news-im-oktober-2017/new-hope-of-a-treatment-for-aggressive-t-pll-leukaemia/?cHash=f8d4e61b53091ec9fd866acbc742ffc8&tx_news_pi1%5BoverwriteDemand%5D%5Bcategories%5D=2

New hope of a treatment for aggressive T-PLL leukaemia ... Hilgarth, Wolfgang R. Sperr, Peter Valent, Ingrid Simonitsch-Klupp, Richard Moriggl, Olaf Merkel, Lukas Kenner, Ulrich Jäger, Stefan Kubicek, Philipp B. Staber. Online: https://www.ncbi.nlm.nih.gov/pubmed/28972014. Blood (IF: 13.2). DOI: 10.1182/blood-2017-05-785683 Share Whatsapp Facebook Twitter... https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/2017/news-im-oktober-2017/new-hope-of-a-treatment-for-aggressive-t-pll-leukaemia/?L=3

New hope of a treatment for aggressive T-PLL leukaemia ... Hilgarth, Wolfgang R. Sperr, Peter Valent, Ingrid Simonitsch-Klupp, Richard Moriggl, Olaf Merkel, Lukas Kenner, Ulrich Jäger, Stefan Kubicek, Philipp B. Staber. Online: https://www.ncbi.nlm.nih.gov/pubmed/28972014. Blood (IF: 13.2). DOI: 10.1182/blood-2017-05-785683 Share Whatsapp Facebook Twitter... https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/2017/news-im-oktober-2017/new-hope-of-a-treatment-for-aggressive-t-pll-leukaemia/medicine-science/?L=3

Established cancer drugs effective in aggressive leukaemia with STAT5 mutations ..., Thomas Kolbe, Mohamed Elabd, Florian Halbritter, Jan Pencik, Zahra Kazemi, Florian Grebien, Markus Hengstschläger, Lukas Kenner, Stefan Kubicek, Matthias Farlik, Christoph Bock, Peter Valent, Mathias Müller, Thomas Rülicke, Veronika Sexl and Richard Moriggl in J Clin Invest. 2018;128(1): https://doi... https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/2017/news-im-dezember-2017/established-cancer-drugs-effective-in-aggressive-leukaemia-with-stat5-mutations/?cHash=8b18113088771f49ee55409febaf3218&tx_news_pi1%5BoverwriteDemand%5D%5Bcategories%5D=11

Established cancer drugs effective in aggressive leukaemia with STAT5 mutations ..., Thomas Kolbe, Mohamed Elabd, Florian Halbritter, Jan Pencik, Zahra Kazemi, Florian Grebien, Markus Hengstschläger, Lukas Kenner, Stefan Kubicek, Matthias Farlik, Christoph Bock, Peter Valent, Mathias Müller, Thomas Rülicke, Veronika Sexl and Richard Moriggl in J Clin Invest. 2018;128(1): https://doi... https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/2017/news-im-dezember-2017/established-cancer-drugs-effective-in-aggressive-leukaemia-with-stat5-mutations/?tx_news_pi1%5BoverwriteDemand%5D%5Bcategories%5D=2&cHash=b8f1400e3809661b73e3558d8f49d599

Established cancer drugs effective in aggressive leukaemia with STAT5 mutations ..., Thomas Kolbe, Mohamed Elabd, Florian Halbritter, Jan Pencik, Zahra Kazemi, Florian Grebien, Markus Hengstschläger, Lukas Kenner, Stefan Kubicek, Matthias Farlik, Christoph Bock, Peter Valent, Mathias Müller, Thomas Rülicke, Veronika Sexl and Richard Moriggl in J Clin Invest. 2018;128(1): https://doi... https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/2017/news-im-dezember-2017/established-cancer-drugs-effective-in-aggressive-leukaemia-with-stat5-mutations/?cHash=b8f1400e3809661b73e3558d8f49d599&tx_news_pi1%5BoverwriteDemand%5D%5Bcategories%5D=2

Established cancer drugs effective in aggressive leukaemia with STAT5 mutations ..., Thomas Kolbe, Mohamed Elabd, Florian Halbritter, Jan Pencik, Zahra Kazemi, Florian Grebien, Markus Hengstschläger, Lukas Kenner, Stefan Kubicek, Matthias Farlik, Christoph Bock, Peter Valent, Mathias Müller, Thomas Rülicke, Veronika Sexl and Richard Moriggl in J Clin Invest. 2018;128(1): https://doi... https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/2017/news-im-dezember-2017/established-cancer-drugs-effective-in-aggressive-leukaemia-with-stat5-mutations/?tx_news_pi1%5BoverwriteDemand%5D%5Bcategories%5D=11&cHash=8b18113088771f49ee55409febaf3218

Established cancer drugs effective in aggressive leukaemia with STAT5 mutations ..., Thomas Kolbe, Mohamed Elabd, Florian Halbritter, Jan Pencik, Zahra Kazemi, Florian Grebien, Markus Hengstschläger, Lukas Kenner, Stefan Kubicek, Matthias Farlik, Christoph Bock, Peter Valent, Mathias Müller, Thomas Rülicke, Veronika Sexl and Richard Moriggl in J Clin Invest. 2018;128(1): https://doi... https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/2017/news-im-dezember-2017/established-cancer-drugs-effective-in-aggressive-leukaemia-with-stat5-mutations/?L=3

Established cancer drugs effective in aggressive leukaemia with STAT5 mutations ..., Thomas Kolbe, Mohamed Elabd, Florian Halbritter, Jan Pencik, Zahra Kazemi, Florian Grebien, Markus Hengstschläger, Lukas Kenner, Stefan Kubicek, Matthias Farlik, Christoph Bock, Peter Valent, Mathias Müller, Thomas Rülicke, Veronika Sexl and Richard Moriggl in J Clin Invest. 2018;128(1): https://doi... https://www.meduniwien.ac.at/web/en/about-us/news/detailsite/2017/news-im-dezember-2017/established-cancer-drugs-effective-in-aggressive-leukaemia-with-stat5-mutations/medicine-science/?L=3

News ... Verbindung mit ALK-positivem Lungenkrebs betroffen. Bereits im Vorjahr war der MedUni Wien bei der Behandlung der aggressiven Lymphkrebs-Form ALCL mit einer auf ein ALK-Gen (NPM-ALK) ausgerichteten Therapie mit einem spezifischen PDFGR-Inhibitor ein Aufsehen erregender Erfolg in der Gruppe um Lukas Kenner... https://www.meduniwien.ac.at/web/index.php?id=131&L=3&tx_news_pi1%5Bnews%5D=1334&tx_news_pi1%5Bcontroller%5D=News&tx_news_pi1%5Baction%5D=detail&cHash=f4afb038e832c2bb844102cf26511f14

Personen